TrialMultiple sclerosis (Houndmills, Basingstoke, England)2019

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Jeffrey A Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.